Table 1

Patient characteristics

US-NBUS-P&FAGSBTotalP valuesMissing (%)
Biopsy procedures, n (%)402 (76.7)65 (12.4)57 (10.9)524 (100.0)
Age, mean (SD)55.93 (13.79)52.43 (12.07)52.30 (17.00)55.12 (14.00)0.051.9
Gender, n (%)
 Female, n (%)285 (72.5)35 (53.8)38 (70.4)358 (69.9)0.012.3
Diagnosis, n (%)
 Rheumatoid arthritis, n (%)360 (89.6)42 (64.6)27 (47.4)429 (81.9)
 Undifferentiated arthritis, n (%)20 (5.0)8 (12.3)2 (3.5)30 (5.7)
 Spondyloarthritis, n (%)7 (1.7)0 (0.0)2 (3.5)9 (1.7)
 Psoriatic arthritis, n (%)7 (1.7)9 (13.8)2 (3.5)18 (3.4)
 Degenerative, n (%)0 (0.0)0 (0.0)13 (22.8)13 (2.5)
 Other, n (%)8 (2.0)6 (9.2)11 (19.3)25 (4.8)<0.010
 Disease duration (years)8.21 (9.74)0.53 (1.35)9.09 (9.40)7.25 (9.42)<0.018.5
Time from diagnosis to biopsy
 Under 1 month, n (%)53 (13.2)40 (61.5)1 (1.8)94 (17.9)
 One to 12 months, n (%)42 (10.4)15 (23.1)11 (19.3)68 (13.0)
 Over 1 year, n (%)307 (76.4)10 (15.4)45 (78.9)362 (69.1)<0.010
Joint biopsied
 Wrist, n (%)277 (69.3)1 (1.5)18 (31.6)296 (56.7)
 Knee, n (%)34 (8.5)56 (86.2)39 (68.4)129 (24.7)
 MCP, n (%)74 (18.5)0 (0.0)0 (0.0)74 (14.2)
 Ankle, n (%)2 (0.5)8 (12.3)0 (0.0)10 (1.9)
 Elbow, n (%)8 (2.0)0 (0.0)0 (0.0)8 (1.5)
 MTP, n (%)5 (1.3)0 (0.0)0 (0.0)5 (1.0)<0.010.4
Disease activity score (DAS28-CRP/ESR), n (%)
 EULAR remission28 (10.4)4 (6.3)2 (5.7)34 (9.3)
 EULAR low disease activity14 (5.2)7 (11.1)7 (20.0)28 (7.6)
 EULAR moderate disease activity98 (36.4)31 (49.2)18 (51.4)147 (40.1)
 EULAR high disease activity129 (48.0)21 (33.3)8 (22.9)158 (43.1)<0.0129
Treatment
 Naive131 (35.2)58 (89.2)25 (51.0)214 (44.0)<0.017.2
 csDMARDs218 (58.6)7 (10.8)23 (46.9)248 (51.0)<0.017.2
 Oral corticosteroid64 (15.9)2 (3.1)13 (22.8)79 (15.1)<0.017.2
 bDMARDs53 (14.2)1 (1.5)1 (2.0)55 (11.3)<0.017.2
IM or IA corticosteroid at biopsy procedure
 IM corticosteroid at biopsy, n (%)55 (13.7)3 (4.6)4 (7.0)62 (11.8)
 IA corticosteroid at biopsy, n (%)26 (6.5)0 (0.0)12 (21.1)38 (7.3)<0.010
  • AGSB, arthroscopic-guided synovial biopsy; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; IA, intra-articular; IM, intramuscular; MCP, metacarpophalangeal; MTP, metatarsophalangeal; US-NB; ultrasound-guided needle biopsy; US-P&F, ultrasound-guided portal and forceps.